Targets for Cancer IO – A Deep Dive Series

Registration RatesBrowse WebinarsProgram FlyerOrganizersPast ProgramsContact Us

Targets for Cancer IO: A Deep Dive Series 5, is supported, in part, by these sponsors (as of Feb. 19, 2025):

Gold Sponsor:

Silver Sponsors:

Bronze Sponsor:

Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.

This series will include six live webinars addressing various hot topics in immuno-oncology.

The Society for Immunotherapy of Cancer (SITC) is pleased to announce our fifth Targets for Cancer IO: A Deep Dive live webinar series.

Key leaders in the field who are experts in their respective fields will provide an overview of the current state of the science and address questions about its future. 

An interactive Q&A session will follow the topic overview, providing participants with the opportunity to ask in-depth questions of the faculty as well as offering a forum for networking and initiation of collaborations with others working in a similar field.

Target Audience

Basic, clinical and translational researchers in academia and industry and members of the investment community.

Enduring Materials

Four weeks following the live webinars, the enduring materials from the webinar, including recording and presentation (as permitted by speakers) will be made available for purchase. 

To note, for those that registered for/attended the webinar, access is granted immediately following the posting of the materials and can be accessed through the "My Library" button under "The Connect Community" tab at the top of the page. An email will be sent once they are posted following the live program - please allow up to one week for them to be posted.

Program Organizers

Mario Sznol, MD

Chair

Mario Sznol, MD
Yale School of Medicine

Dan Chen, MD, PhD

Co-Chair

Daniel S. Chen, MD, PhD
Synthetic Design Lab

Elizabeth Jaffee, MD, FAIO

Elizabeth M. Jaffee, MD, FAIO
Sidney Kimmel Cancer Center, Johns Hopkins University

Nils Lonberg, PhD

Nils Lonberg, PhD
Canaan

Ira Mellman, PhD

Ira Mellman, PhD, FAIO
Medici Therapeutics/Parker Institute for Cancer Immunotherapy

Howard Kaufman, MD, FACS

Katy Rezvani, MD, PhD
The University of Texas MD Anderson Cancer Center

Browse Webinars

LIVE WEBINAR 1

Mechanisms of Resistance at the T-cell/Tumor Interface

Webinar 1 will investigate the molecular interactions that occur between the tumor cells and T cells that define response and reistance to cancer immunotherapy. The most recent data surrounding intratumoral T cells and their functions in anti-tumor immunity and current cellular engineering approaches to overcome resistance to CAR T cell therapy and enhance anti-tumor activity will also be discussed.

Date of Live Event
Tuesday, Feb. 18, 2025 – 12–2 p.m. EST

Ben Izar, MD, PhD

Moderator
Ben Izar, MD, PhD
Columbia University

Weiping Zou, MD, PhD

Moderator
Weiping Zou, MD, PhD
University of Michigan

Niro Anandasabapathy, MD, PhD

Faculty
Niro Anandasabapathy, MD, PhD
Weill Cornell Medicine

Marco Ruella, MD

Faculty
Marco Ruella, MD
University of Pennsylvania Perelman School of Medicine

PURCHASE ENDURING MATERIALS

LIVE WEBINAR 2

Updated Results on Cis-targeted IL-2s

Clinical benefits of the T cell activating cytokine IL-2 have not yet been fully realized, mostly due to the potential of T cell-mediated off-target toxicities and other safety concerns. Webinar 2 will feature discussions of translational and clinical studies of IL-2-based fusion proteins that selectively and potently activate anti-tumor cytotoxic T cells and their potential to enhance the efficacy of exisiting cancer immunotherapies.

Date of Live Event
Tuesday, March 4, 2025 – 12–2 p.m. EST

Harriet Kluger, MD

Moderator
Harriet Kluger, MD
Yale University

Mohammad Rashidian, PhD

Moderator
Mohammad Rashidian, PhD
Dana-Farber Cancer Institute

Ivana Djuretic, PhD

Faculty
Ivana Djuretic, PhD
Asher Bio

Mélanie Tichet, PhD

Faculty
Mélanie Tichet, PhD
Georg-Speyer-Haus Frankfurt Germany

PURCHASE ENDURING MATERIALS

LIVE WEBINAR 3

What's Next for TIL or Adoptive Cell Therapy After the Iovance Approval?

Date of Live Event
Wednesday, March 26, 2025 – 12–2 p.m. EST

FDA approval of tumor infiltrating lymphocyte (TIL) therapy liflileucel for melanoma marked the first time a cellular therapy has been approved for treatment of solid tumors. Approximately one year later, Webinar 3 will discuss the current state and the future of TIL therapy, including the biology of TIL therapy, current approaches to develop the next generation of TIL therapies, and practical, regulatory, and scientific considerations when implementing TIL therapy in the clinic.

Rodabe N. Amaria, MD

Moderator
Rodabe N. Amaria, MD
The University of Texas MD Anderson Cancer Center

Friedrich Graf Finckenstein, MD

Moderator
Friedrich Graf Finckenstein, MD
Iovance Biotherapeutics

Alison Betof-Warner, MD, PhD

Faculty
Alison Betof-Warner, MD, PhD
Stanford University

Bruce Brockstein, MD

Faculty
Bruce Brockstein, MD
Northshore Health

George Coukos, MD, PhD

Faculty
George Coukos, MD, PhD
Ludwig Cancer Research, University of Lausanne

Stephanie Goff, MD

Faculty
Stephanie Goff, MD
National Institutes of Health

Raj Puri, MD, PhD

Faculty
Raj Puri, MD, PhD
Iovance Biotherapeutics

PURCHASE ENDURING MATERIALS

LIVE WEBINAR 4

T-cell Engagers and Targeted Immune Modulation for Prostate Cancer

Date of Live Event
Monday, May 12, 2025 – 11a.m.–1 p.m. EST

Much progress has been made in the development of bispecific T cell engagers and immune modulators for the treatment of prostate cancer. Webinar 4 will address lessons learned from past preclinical and clinical studies of T cell engagers and immune modulators for solid tumors and how these insights have informed the identification and testing of these promising new therapies. Presentations will discuss current and newly identified targets for prostate cancer and other considerations surrounding the use of these agents in the clinic, including clinical efficacy of these agents in combination with other immunotherapies.

Charles G. Drake, MD, PhD

Moderator
Charles G. Drake, MD, PhD
Johnson and Johnson Innovative Medicine

Sumit K. Subudhi, MD, PhD

Moderator
Sumit K. Subudhi, MD, PhD
University of Texas MD Anderson Cancer Center

Andrew J. Armstrong, MD, ScM, FACP

Faculty
Andrew J. Armstrong, MD, ScM, FACP
Duke University

William Kelly, DO

Faculty
William Kelly, DO
Thomas Jefferson University

REGISTER

LIVE WEBINAR 5

In Vivo Gene Modification as a Method of Generating CAR-T Cells

Date of Live Event
Tuesday, June 17, 2025 – 12–2 p.m. EST

This webinar will investigate the mechanisms underlying tertiary lymphoid aggregate structure and function within the tumor, and how they translate to clinical benefits. Ongoing therapeutic approaches to stimulate aggregate formation or activate B cells or other immune cells within the aggregates will also be discussed.

Moderator
Daniel Powell, PhD
University of Pennsylvania

Moderator
Justin Eyquem, PhD
University of California, San Francisco

REGISTER

LIVE WEBINAR 6

Development of Anti-CCR8 Ab - Mechanisms and Clinical Results

Date of Live Event
Wednesday, Oct. 22, 2025 – 12–2 p.m. EST

This webinar will investigate the mechanisms underlying tertiary lymphoid aggregate structure and function within the tumor, and how they translate to clinical benefits. Ongoing therapeutic approaches to stimulate aggregate formation or activate B cells or other immune cells within the aggregates will also be discussed.

Moderator
Rahul Roychoudhuri, MD, PhD
University of Cambridge

Moderator
Enrico Lugli, PhD
Humanitas Hospital

REGISTER

Registration Rates

BUY THREE, GET THREE FREE

As an added benefit, SITC members are eligible to receive a discount on the full series, as well as individual webinars, if purchased separately. Additionally, at the time of registration, if three of the six webinars are purchased, you are able to register for the remaining three webinars at no additional cost.

SITC Member Pricing - Targets for Cancer IO: A Deep Dive
  Live Registration Rates Enduring Materials Rates
Fellow in training/student  $25 per (3 webinars for $75) $12.50 per
Government  $40 per (3 webinars for $120) $20 per 
Health care provider $75 per (3 webinars for $225) $37.50 per 
Industry rep  $150 per (3 webinars for $450) $75 per 
Non-profit org/foundation $25 per (3 webinars for $75) $12.50 per 
Pharmacist $75 per (3 webinars for $225) $37.50 per 
Pharmacist, industry $150 per (3 webinars for $450) $75 per 
Patient/Patient advocate $25 per (3 webinars for $75) $12.50 per 
Nurse  $25 per (3 webinars for $75) $12.50 per
Nurse, industry $150 per (3 webinars for $450) $75 per 
Low to lower-middle income economies (non-industry) $0 $0
SITC Non-Member Pricing - Targets for Cancer IO: A Deep Dive
  Live Registration Rates Enduring Materials Rates
Fellow in training/student  $40 per (3 webinars for $120) $20 per 
Government  $50 per (3 webinars for $150) $25 per 
Health care provider $100 per (3 webinars for $300) $50 per 
Industry rep  $300 per (3 webinars for $900) $150 per 
Non-profit org/foundation $40 per (3 webinars for $120) $20 per 
Pharmacist $100 per (3 webinars for $300) $50 per 
Pharmacist, industry $300 per (3 webinars for $900) $150 per 
Patient/Patient advocate $40 per (3 webinars for $120) $20 per 
Nurse  $40 per (3 webinars for $120) $20 per 
Nurse, industry $300 per (3 webinars for $900) $150 per 
Low to lower-middle income economies (non-industry) $25 per (3 webinars for $75)
 $12.50 per

Past Programs

2024  2023  2022  2021